---
title: "Shen Lian Biomedical: The Phase II clinical study of the innovative drug UB-221 injection has completed the enrollment of all subjects"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255349828.md"
description: "On August 31, Shen Lian Biomedical announced that its investee company, Shizhiyuan, has completed the enrollment of 145 subjects in the Phase II clinical study of the innovative drug UB-221 injection. The marketing authorization and commercialization rights of UB-221 in mainland China are owned by Shizhiyuan. This drug is developed by United Biomedical, Inc. in the United States and is a subcutaneous injection formulation of a humanized original monoclonal antibody targeting anti-IgE therapy"
datetime: "2025-08-31T09:54:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255349828.md)
  - [en](https://longbridge.com/en/news/255349828.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255349828.md)
generator: "portal-rs"
---

# Shen Lian Biomedical: The Phase II clinical study of the innovative drug UB-221 injection has completed the enrollment of all subjects

On August 31, Shen Lian Biomedical announced that the company recently received a "Notice" from its investee company, Shizhiyuan, regarding the progress of the Phase II clinical study of the innovative drug UB-221 injection. As of the date of this announcement, the project has completed the enrollment of all 145 subjects. Shizhiyuan holds the marketing authorization and all commercialization rights for UB-221 in mainland China, including research and development, production, and sales. UB-221 is a proprietary drug developed by the company's second largest shareholder, United Biomedical, Inc. This project is a next-generation product developed by Dr. Zhang Ziwen, the inventor of the anti-IgE therapy, and is a humanized original monoclonal antibody in a subcutaneous injection form

### Related Stocks

- [688098.CN](https://longbridge.com/en/quote/688098.CN.md)

## Related News & Research

- [Negative Link Announces Global Expansion and Next Phase of Growth](https://longbridge.com/en/news/296644416.md)
- [14:41 ETNine Corboy & Demetrio Attorneys selected to 2027 The Best Lawyers in America®](https://longbridge.com/en/news/296644470.md)
- [08:12 ETAXIS-Y Expands GCC Presence with Landmark Kuwait and Bahrain Launch](https://longbridge.com/en/news/296616640.md)
- [FONDIA: Profitability improved sharply in H1 2026, driven by growth in Finland and the Baltics](https://longbridge.com/en/news/296439068.md)
- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**